Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months

Eribulin is a non-taxane microtubule inhibitor approved for the treatment of metastatic breast carcinoma after two prior chemotherapeutic regimens. We report a patient with extended progression-free survival (PFS) of more than 57 months with metastatic breast carcinoma treated with eribulin in the t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cureus
Main Authors: Manthri, Sukesh, Sharma, Purva, Mejbel, Haider Atheer, Singal, Sakshi, Jaishankar, Devapiran
Format: Artigo
Jezik:Inglês
Izdano: Cureus 2020
Teme:
Internal Medicine
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7075509/
https://ncbi.nlm.nih.gov/pubmed/32201658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.6980
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki